Celldex Therapeutics (CLDX) Other Accumulated Expenses (2010 - 2026)

Celldex Therapeutics' Other Accumulated Expenses history runs 17 years deep, the most recent figure standing at $1.2 million for Q1 2026.

• In Q1 2026, Other Accumulated Expenses fell 25.59% year-over-year to $1.2 million; the TTM figure through Mar 2026 stood at $1.2 million (down 25.59% YoY), while the FY2025 annual figure was $1.2 million, up 263.91% from the prior year.
• Other Accumulated Expenses was $1.2 million for Q1 2026 at Celldex Therapeutics, roughly flat from $1.2 million in the prior quarter.
• In the past five years, Other Accumulated Expenses ranged from a high of $4.2 million in Q3 2023 to a low of $338000.0 in Q4 2024.
• Historically, Other Accumulated Expenses has averaged $1.9 million across 5 years, with a median of $1.2 million in 2025.
• The sharpest annual moves came in 2023 and 2024: Other Accumulated Expenses jumped 302.83% in 2023, then plunged 91.52% in 2024.
• A 5-year view of Other Accumulated Expenses shows it stood at $990000.0 in 2022, then soared by 302.83% to $4.0 million in 2023, then slumped by 91.52% to $338000.0 in 2024, then jumped by 263.91% to $1.2 million in 2025, then changed by 0.0% to $1.2 million in 2026.
• The last three Other Accumulated Expenses figures came in at $1.2 million (Q1 2026), $1.2 million (Q4 2025), and $930000.0 (Q3 2025), per Business Quant data.